A New Chapter in Menopause Discussions: From Private Topic to Public Dialogue
Celebrities and experts are gathering at Iguatemi Talks Wellness to openly discuss the health and longevity of middle-aged women. This signals a growing trend toward destigmatizing age-related changes and increasing interest in preventive medicine and quality of life during menopause.
Menopause 2.0: Why Celebrity Conversations Have Turned into a Billion-Dollar Market
While stars and experts convene at Iguatemi Talks Wellness in São Paulo on June 23, 2026, to discuss menopause and longevity for middle-aged women, something far more fundamental is happening in the industry than just another "trend toward openness." This isn't destigmatization—it's the capitalization of silence.
[The Core]: What's Really Happening
Behind the glossy image of "celebrities speaking up about important issues" lies a market anomaly that economists would call a "resource allocation failure." According to recent data, 70% of women in the US aged 35-54 experience menopause symptoms affecting mood and cognitive function, but only 30% seek help. This isn't just a gap—it's a chasm.
The media presents the Iguatemi event as a "breakthrough in public dialogue." In reality, it's a marker that big capital (JK Iguatemi—a premium shopping mall) has seen menopause not as a social problem, but as a vertically integrable market. Because the numbers speak for themselves: the global women's health market was valued at $56.85 billion in 2025 and is projected to reach $98.61 billion by 2034. The menopause market as a separate segment will grow from $18.78 billion in 2025 to $26.21 billion in 2030. The broader category of "menopause-adjacent products and services" is estimated at a staggering $490.15 billion in 2025, with a growth forecast to $708.67 billion by 2032.
The key non-obvious insight that media will miss:
The menopause market doesn't suffer from a lack of products. It suffers from a "behavioral divide": women don't recognize their symptoms as treatable due to cognitive dissonance and cultural silence that has lasted for generations. 66% of women feel unprepared for perimenopause and menopause. They don't go to the doctor not because they're embarrassed, but because their brain says, "This is just aging, deal with it." And here lies the real opportunity—not to sell a pill, but to reshape the perception of reality.
Google AdInline article slot
Timeline and Context
Phase 1 (2023–2024): The Silent Epidemic and Workforce Exodus. Research shows that nearly 1 million women in the UK have left the labor market due to menopause symptoms. Employers are starting to panic. The loss of skilled workers aged 45-55 costs the economy billions.
Phase 2 (2025): The FemTech Explosion. Midi Health raises $100 million in a Series D round in February 2026. Pomelo Care secures $92 million at a $1.7 billion valuation. Investors realize: menopause is not a niche; it's a demographic tsunami. 13 million women in the UK alone are currently in perimenopause or menopause.
Phase 3 (March–May 2026): The Bifurcation Point. In March, Prickly Pear Health expands its pre-seed round to $600k with support from Emmeline Ventures, building an AI platform for women's brain health. That same month, Coral raises an additional $4 million CAD for a virtual menopause clinic. TENA publishes a study on the "behavioral inefficiency" of the market, showing that 76% of perimenopausal women don't feel represented in brand advertising.
Present (May 2026): Iguatemi Talks Wellness brings together Claudia Raia, Carolina Ferraz, and Dr. André Vinícius on one stage. This isn't a conversation. It's a product launch disguised as a panel discussion.
Who Wins and Who Loses
Winners:
- Vertically integrated FemTech startups. Midi Health, Pomelo Care, Origin (secured Series B for pelvic floor therapy). They don't sell "hot flash cream." They sell a subscription for comprehensive management—from doctor to AI symptom tracker. The average subscription price in the US: $49-99 per month.
- Employers implementing menopause support programs. This isn't altruism. Studies show that nearly a quarter of working women have considered reducing their hours due to symptoms, and over half report negative impacts on their sex life and relationships. A company that adopts supportive policies reduces turnover by 15-20% in the 45-55 age group. Savings from replacing one top manager: $100k-200k.
- Brands shifting from clinical language to storytelling. TENA conducted a study using "narrative priming" methodology, asking women to describe menopause in movie genres. Result: advertising that hit the press and broke stereotypes. Because a "medical problem" doesn't sell, but a "personal story" does.
Losers:
- Traditional pharma tied to HRT (hormone therapy). The market is moving toward non-hormonal, lifestyle solutions and dietary supplements. Younger audiences (35-45) fear hormones due to old studies. They're willing to pay for "biohacking" protocols.
- Clinics without an online component. Telemedicine is killing offline gynecology in the "I just need a progesterone prescription" segment. Remember: online sales channels are a key market growth driver.
- Menstrual tracking apps that haven't updated for menopause. The market is shifting from "fertility" to "post-fertility." Those stuck on ovulation tracking will lose their audience by 2027.
What the Media Isn't Saying
Two hard facts that won't make it into glossy reports from Iguatemi Talks.
First: Privacy and discrimination issues. A study by Royal Holloway University of London, published March 6, 2026, revealed serious risks: menopause data collected by apps (including emotional symptoms and sexual activity history) could be used by insurance companies and employers for discrimination. Women fear being fired or having their premiums raised if it's known they're in menopause. And these fears are not unfounded. Moreover, unlike fertility trackers, menopause apps remain virtually unregulated. No law prohibiting the transfer of this data to insurers exists in the US yet.
Second: Digital isolation and medical misinformation. The same study showed that many menopause platforms don't have a single licensed physician moderating the community. Women come for advice and get "neighbor's experience," which can be dangerous. 57% of women say menopause remains a taboo topic, which is why they go online—it feels safer. But safer ≠ safe. The lack of medical oversight in these "digital safe havens" creates an ideal environment for spreading dubious supplements and dangerous schemes.
Third, the most cynical insight: The very fact that Iguatemi Talks Wellness brings together celebrities, a gynecologist, and beauty industry representatives on one stage means menopause has ceased to be a medical problem and has become a marketing category. JK Iguatemi is not a hospital. It's a marketplace. And when Claudia Raia talks about "embracing age," brands will be sitting nearby ready to sell a "solution" for $200. The media will call it "destigmatization." I call it the colonization of women's health by marketing.
Forecast: Next 30 Days and 90 Days
Next 30 Days (June 2026):
Expect a wave of "menopause content" from all major beauty and wellness publications. Vogue, Harper's Bazaar, Byrdie will launch special projects. Cosmetic brands will start including the word "menopause" in SEO strategies. There will be lots of talk about "empowerment" and few concrete recommendations. Key event: Iguatemi Talks Wellness on June 23. Don't watch the panel; watch the event sponsors.
Next 90 Days (Summer–Fall 2026):
Market consolidation will begin. Small FemTech projects without evidence bases will be absorbed by larger players.
- Deal forecast: Midi Health (just raised $100 million) will start acquiring tracker apps with user bases. Valuation of such an app with 500k MAU: $10-15 million.
- Tech trend: Integration of AI and voice analytics. Prickly Pear Health is already building a platform that tracks changes in cognitive function and mood through voice and wearable data. The next 90 days will show if they can scale with a $600k pre-seed.
- Risk (and it's huge): A data leak or a major scandal involving discrimination based on menopause tracking. If any insurance company or HR department is caught using this data, a regulatory crackdown will follow. Then the "openness revolution" will collide with the "privacy counter-revolution."
What an insider should do: Don't watch Iguatemi Talks. Watch the lawmakers in California—they'll be the first to regulate menopause data. And watch TENA: their "narrative priming" research methodology will become the standard for the entire wellness communications market in 2027. Because you can no longer sell "health." You can only sell a "story" in which a woman recognizes herself. And menopause is the perfect unwritten script.
— Editorial Team
